Search Result
Results for "
Macrocyclic inhibitors
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
3
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-I0179
-
|
HCV Protease
|
Infection
|
ITMN 4077 is a macrocyclic inhibitor against Hepatitis C Virus (HCV) NS3 protease (EC50: 2131 nM) .
|
-
-
- HY-15739
-
-
-
- HY-162234
-
|
PKC
|
Others
|
PKCTheta-IN-1 (Compound 19) is a selective macrocyclic PKCTheta inhibitor with IC50 value of 0.1 nM .
|
-
-
- HY-161079
-
|
Parasite
|
Infection
|
TDI-8304, a macrocyclic peptide, is a potent, species selective, and noncovalent Plasmodium falciparum (Pf20S) inhibitor. TDI-8304 shows highly selective for Pf20S over human proteasomes .
|
-
-
- HY-176417
-
|
Fungal
Antibiotic
|
Infection
|
Antifungal agent 132 (compound 25) is a selective and potent antifungal agent. Antifungal agent 132 inhibits Cryptococcus neoformans May1 with a Ki of 180 pM .
|
-
-
- HY-147429A
-
Abx MCP TFA; RG6006 TFA
|
Antibiotic
Bacterial
|
Infection
|
Zosurabalpin TFA is a tethered macrocyclic peptide antibiotic, acting specifically on A. baumannii. Zosurabalpin TFA inhibits lipopolysaccharide-transport .
|
-
-
- HY-P3356
-
|
Elastase
Proteasome
|
Inflammation/Immunology
|
Cyclotheonellazole A is a natural macrocyclic peptide and a potent elastase inhibitor (IC50=0.034 nM). Cyclotheonellazole A inhibits chymotrypsin with an IC50 value of 0.62 nM .
|
-
-
- HY-156105
-
|
Parasite
Proteasome
|
Infection
|
8304-vs is a macrocyclic anti-Plasmodial agent that covalently and irreversibly targets the Plasmodium proteasome. 8304-vs effectively inhibits the growth of Plasmodium falciparum .
|
-
-
- HY-P3270
-
|
Bacterial
Antibiotic
|
Infection
|
Capreomycin is a macrocyclic peptide antibiotic. Capreomycin can be used for anti-multidrug-resistant-tuberculosis research. Capreomycin can inhibit phenylalanine synthesis in in mycobacterial ribosomes translation
|
-
-
- HY-P2331
-
Antibiotic A 3802-IV-3; Gardimycin
|
Antibiotic
|
Infection
|
Actagardin is a tetracyclic lantibiotic produced by several species of Actinoplanes. It is composed of macrocyclic rings formed by thioether bridges. Actagardin preferably targets Gram-positive bacteria, inhibiting the synthesis of peptidoglycan.
|
-
-
- HY-145263
-
|
Ser/Thr Protease
|
Cancer
|
VD2173 is a side chain cyclized macrocyclic peptide inhibitor of HGF-activating serine proteases. VD2173 potently inhibits matriptase and hepsin. VD2173 can be used for the research of lung cancer .
|
-
-
- HY-139105
-
|
Microtubule/Tubulin
|
Infection
Cancer
|
20-O-Demethyl-AP3 is a minor metabolite of Ansamitocin P-3. Ansamitocin P-3, a microtubule inhibitor, is a macrocyclic antitumor antibiotic .
|
-
-
- HY-158150
-
|
Proteasome
|
Cancer
|
20S Proteasome-IN-5 (Compound 5) is a macrocyclic inhibitor of the 20S Proteasome, with IC50 values of 0.19 and 52.5 μM for ChT-L and PGPH-L activity, respectively .
|
-
-
- HY-13756A
-
FK506 monohydrate; Fujimycin monohydrate; FR900506 monohydrate
|
Phosphatase
FKBP
Autophagy
Bacterial
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
Tacrolimus monohydrate (FK506 monohydrate), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex and inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
|
-
-
- HY-13756
-
-
-
- HY-P3502
-
RA101495; RA3193
|
Complement System
|
Inflammation/Immunology
|
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .
|
-
-
- HY-172320
-
|
PD-1/PD-L1
|
Cancer
|
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .
|
-
-
- HY-19628A
-
|
RIP kinase
TGF-β Receptor
|
Inflammation/Immunology
|
OD36hydrochloride is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with KDs of 37 nM .
|
-
-
- HY-19628
-
|
RIP kinase
TGF-β Receptor
|
Inflammation/Immunology
|
OD36 is a RIPK2 inhibitor with an IC50 of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 shows ALK2-directed activity with KDs of 37 nM .
|
-
-
- HY-P3502A
-
RA101495 TFA; RA3193 TFA
|
Complement System
|
Inflammation/Immunology
|
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .
|
-
-
- HY-P5963
-
-
-
- HY-N7765
-
|
HCV
Bacterial
Apoptosis
Fungal
|
Infection
Inflammation/Immunology
Cancer
|
Oenothein B is a dimeric macrocyclic ellagitannin and has widely pharmacological activities, including antioxidant, anti-inflammatory, antifungal, anti-HCV, and antitumor properties. Oenothein B is a potent and specific inhibitor of poly(ADP-ribose) glycohydrolase .
|
-
-
- HY-173076
-
|
HDAC
YAP
|
Inflammation/Immunology
|
HDAC11-IN-1 (Compound 14-N C6OH) is a selective macrocyclic inhibitor of HDAC11 with a Ki of 40 nM. HDAC11-IN-1 exhibits good cell permeability and can inhibit the expression of YAP1 and SOX2 .
|
-
-
- HY-P10375
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 .
|
-
-
- HY-133015
-
|
Bcl-2 Family
|
Cancer
|
Mcl-1 inhibitor 3 (compound 1) is a highly potent and orally activate macrocyclic Mcl-1 inhibitor (Ki= 0.061 nM; IC50=19 nM in an OPM-2 cell viability assay). Mcl-1 inhibitor 3 shows good pharmacokinetic properties and excellent in vivo efficacy without toxicity ..
|
-
-
- HY-15739R
-
Antibiotic C 15003P3 (Standard); Maytansinol isobutyrate (Standard)
|
Microtubule/Tubulin
ADC Cytotoxin
Bacterial
Antibiotic
|
Infection
Cancer
|
Ansamitocin P-3 (Standard) is the analytical standard of Ansamitocin P-3. This product is intended for research and analytical applications. Ansamitocin P-3 (Antibiotic C 15003P3) is a microtubule inhibitor. Ansamitocin P-3 is a macrocyclic antitumor antibiotic.
|
-
-
- HY-107486
-
Multhiomycin; RP 9671
|
Bacterial
Antibiotic
|
Infection
|
Nosiheptide (Multhiomycin), a thiopeptide antibiotic produced by Streptomyces actuosus, inhibits bacterial protein synthesis and bears a unique indole side ring system and regiospecific hydroxyl groups on the characteristic macrocyclic core. Nosiheptide has been widely used as a feed additive for animal growth .
|
-
-
- HY-144614
-
|
DYRK
Apoptosis
|
Neurological Disease
Cancer
|
JH-XVII-10 is a potent, selective and orally active DYRK1A and DYRK1B inhibitor with IC50s of 3 nM and 5 nM for DYRK1A and DYRK1B, respectively. JH-XVII-10 shows antitumor efficacy in neck squamous cell carcinoma (HNSCC) cell lines .
|
-
-
- HY-13756R
-
|
Phosphatase
FKBP
Bacterial
Autophagy
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
Tacrolimus (Standard) is the analytical standard of Tacrolimus. This product is intended for research and analytical applications. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
|
-
-
- HY-107212
-
|
Parasite
Chloride Channel
P-glycoprotein
Bacterial
|
Infection
|
Selamectin, a semi-synthetic macrocyclic lactone, is a potent parasiticide and anthelminthic. Selamectin activates glutamate-gated chloride channels in neurons and pharyngeal muscles to prevent heartworm, Lymphatic filariae, and nematode infection. Selamectin is also a potent P-glycoprotein substrate and a P-glycoprotein inhibitor with an IC50 of 120 nM .
|
-
-
- HY-13756S2
-
-
-
- HY-13756S
-
FK506-13C,d2; Fujimycin-13C,d2; FR900506-13C,d2
|
Phosphatase
FKBP
Bacterial
Autophagy
Antibiotic
|
Infection
Inflammation/Immunology
Cancer
|
Tacrolimus- 13C,d2 is a 13C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
|
-
-
- HY-168902
-
|
Proteasome
|
Cancer
|
Proteasome-IN-7 (Compound 6f) is an epoxyketone macrocyclic peptidyl proteasome inhibitor (IC50 value of 37.92 nM for 20S proteasome ChT-L subunit). Proteasome-IN-7 displays robust antiproliferative effects against multiple myeloma, acute lymphoblastic leukemia and non-small cell lung cancer .
|
-
-
- HY-P10700
-
|
Antibiotic
|
Infection
|
RO7196472 is a potent and selective macrocyclic peptide antibiotic that targets Acinetobacter strains. RO7196472 inhibits Acinetobacter strain activity by specifically binding to the Lipopolysaccharide (LPS) binding site on the LptB2FG complex located on the inner membrane of Acinetobacter strains, thereby blocking LPS transport and suppressing Acinetobacter strain activity .
|
-
-
- HY-17580
-
OPT-80; PAR-101
|
DNA/RNA Synthesis
Bacterial
Apoptosis
Antibiotic
|
Infection
|
Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .
|
-
-
- HY-17566
-
|
Antibiotic
Bacterial
|
Infection
Neurological Disease
Metabolic Disease
|
Capreomycin sulfate is a macrocyclic peptide antibiotic that inhibits phenylalanine synthesis in mycobacterial ribosomal translation. Capreomycin sulfate has anti-amyloidogenic and pro-fibrinolytic activities, reducing amyloid-induced cytotoxicity by inhibiting the occurrence of amyloid fibrillation. Capreomycin sulfate can be used in the study of multidrug-resistant tuberculosis, type 2 diabetes, Alzheimer's disease and Parkinson's disease .
|
-
-
- HY-P10855
-
|
SARS-CoV
|
Infection
|
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .
|
-
-
- HY-144068
-
|
Influenza Virus
|
Infection
|
Cap-dependent endonuclease-IN-25 is a potent inhibitor of cap-dependent endonuclease (CEN). Cap-dependent endonuclease-IN-25 is a macrocyclic pyridotriazine derivative. Cap-dependent endonuclease-IN-25 has the potential for the research of viral infections caused by viruses belonging to the Orthomyxoviridae family (extracted from patent WO2020075080A1, compound 4) .
|
-
-
- HY-N0750
-
Crotaline
|
Others
|
Metabolic Disease
Cancer
|
Monocrotaline is an 11-membered macrocyclic pyrrolizidine alkaloid. Monocrotaline inhibits OCT-1 and OCT-2 with IC50s of 36.8 µM and 1.8 mM, respectively. Monocrotaline has antitumor activity and is cytotoxic to hepatocellular carcinoma cells. Monocrotaline is used to induce a model of pulmonary hypertension in rodents. [2][6][8].
|
-
-
- HY-W034576
-
Hexaaza-18-crown-6 hexahydrochloride; 1,4,7,10,13,16-Hexaazacyclooctadecane hexahydrochloride
|
Biochemical Assay Reagents
|
Cancer
|
Hexacyclen (Cycloalkene) is an organic compound with a unique macrocyclic structure composed of six nitrogen-containing rings. Hexacyclen is commonly used as a chelating agent in chemistry and biochemistry due to its ability to bind metal ions, and is often used to selectively bind metal ions in proteins or enzymes to study their structure and function. Hexacyclen also acts as an inhibitor of cancer .
|
-
-
- HY-107426
-
Muconomycin A
|
Apoptosis
Reactive Oxygen Species
|
Cancer
|
Verrucarin A (Muconomycin A), a Type D macrocyclic mycotoxin derived from the pathogen fungus Myrothecium verrucaria, is an inhibitor of protein synthesis. Verrucarin A inhibits growth of leukemia cell lines and activates caspases and apoptosis and inflammatory signaling in macrophages. Verrucarin A effectively increased the phosphorylation of p38 MAPK and diminished the phosphorylation of ERK/Akt. Verrucarin A caused cell cycle deregulation through the induction of p21 and p53 .
|
-
-
- HY-161370
-
|
Ser/Thr Protease
|
Cancer
|
VD4162 (Compound 8b) is a macrocyclic inhibitor of serine proteases. VD4162 can significantly improve potency for all four target enzymes TMPRSS2 (IC50 = 3.7 nM), HGFA(IC50 = 3.3 nM), matriptase (IC50 = 2.9 nM), and hepsin (IC50 = 0.54 nM). VD4162 can be used for the research of cancer .
|
-
-
- HY-17580S
-
|
Isotope-Labeled Compounds
Bacterial
Apoptosis
Antibiotic
|
Infection
|
Fidaxomicin-d7 (OPT-80-D7) is the deuterium labeled Fidaxomicin. Fidaxomicin (OPT-80), a macrocyclic RNA polymerase inhibitor, has a narrow spectrum of activity. Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora .
|
-
-
- HY-107486R
-
|
Bacterial
Antibiotic
|
Infection
|
Nosiheptide (Standard) is the analytical standard of Nosiheptide. This product is intended for research and analytical applications. Nosiheptide (Multhiomycin), a thiopeptide antibiotic produced by Streptomyces actuosus, inhibits bacterial protein synthesis and bears a unique indole side ring system and regiospecific hydroxyl groups on the characteristic macrocyclic core. Nosiheptide has been widely used as a feed additive for animal growth .
|
-
-
- HY-107212R
-
|
Parasite
Chloride Channel
P-glycoprotein
Bacterial
|
Infection
|
Selamectin (Standard) is the analytical standard of Selamectin. This product is intended for research and analytical applications. Selamectin, a semi-synthetic macrocyclic lactone, is a potent parasiticide and anthelminthic. Selamectin activates glutamate-gated chloride channels in neurons and pharyngeal muscles to prevent heartworm, Lymphatic filariae, and nematode infection. Selamectin is also a potent P-glycoprotein substrate and a P-glycoprotein inhibitor with an IC50 of 120 nM .
|
-
-
- HY-144617
-
|
DYRK
|
Cancer
|
JH-XIV-68-3 is a selective macrocyclic inhibitor of DYRK1A/B. JH-XIV-68-3 displays selectivity for DYRK1A and close family member DYRK1B in biochemical and cellular assays. JH-XIV-68-3 demonstrates antitumor efficacy in head and neck squamous cell carcinoma (HNSCC) cell lines .
|
-
-
- HY-144739
-
-
-
- HY-144741
-
-
-
- HY-17580R
-
|
DNA/RNA Synthesis
Bacterial
Apoptosis
Antibiotic
|
Infection
|
Fidaxomicin (Standard) is the analytical standard of Fidaxomicin. This product is intended for research and analytical applications. Fidaxomicin (OPT-80), a macrocyclic antibiotic, is an orally active and potent RNA polymerase inhibitor. Fidaxomicin has a narrow spectrum of antibacterial activity and a good anti-Clostridium difficile activity (MIC90=0.12 μg/mL). Fidaxomicin can be used for Clostridium difficile infection (CDI) research .
|
-
-
- HY-P3143
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P3143A
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-149034
-
S5
|
Influenza Virus
|
Infection
Cancer
|
Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM .
|
-
- HY-W034566
-
Hexaaza-18-crown-6; 1,4,7,10,13,16-Hexaazacyclooctadecane
|
Biochemical Assay Reagents
|
Others
|
Hexacyclen is an organic compound with a unique macrocyclic structure composed of six nitrogen-containing rings. It is commonly used as a chelating agent in chemistry and biochemistry due to its ability to bind metal ions. Inhibitors of certain diseases such as cancer. In biochemistry, Hexacyclen is often used to selectively bind metal ions in proteins or enzymes to study their structure and function. Due to its large size and complex structure, Hexacyclen is not widely used in daily products or applications .
|
-
- HY-W034566A
-
Hexaaza-18-crown-6 trisulfate; 1,4,7,10,13,16-Hexaazacyclooctadecane trisulfate
|
Biochemical Assay Reagents
|
Others
|
Hexacyclen, also known as cycloalkene, is an organic compound with a unique macrocyclic structure composed of six nitrogen-containing rings. It is commonly used as a chelating agent in chemistry and biochemistry due to its ability to bind metal ions. Inhibitors of certain diseases such as cancer. In biochemistry, Hexacyclen is often used to selectively bind metal ions in proteins or enzymes to study their structure and function. Due to its large size and complex structure, Hexacyclen is not widely used in daily products or applications.
|
-
- HY-161571
-
|
LRRK2
|
Neurological Disease
|
LRRK2-IN-13 (Compound 13) is an inhibitor of LRRK2 (IC50=0.57 nM). LRRK2-IN-13 has brain penetrating properties .
|
-
- HY-125728
-
|
Bacterial
Parasite
HCV
|
Infection
|
Micrococcin P1 is a macrocyclic peptide antibiotic and is a potent hepatitis C virus (HCV) inhibitor with an EC50 range of 0.1-0.5 μM . Micrococcin P1 has in vitro antibacterial activity against Gram-positive bacterial strains. The MIC values of Micrococcin P1 against S. aureus 1974149, E. faecalis 1674621 and S. pyogenes 1744264 are 2 μg/mL, 1 μg/mL and 1 μg/mL, respectively . Micrococcin P1 is also a potent inhibitor of the malaria parasite Plasmodium falciparum .
|
-
- HY-N8280
-
|
Fungal
|
Infection
|
IKD-8344 is a macrocyclic dilactone originally isolated from an actinomycete species and has diverse biological activities, including anticancer, antimicrobial, and anthelmintic properties. It is cytotoxic to L5178Y murine leukemia cells (IC50=0.54 ng/ml).1 IKD-8344 inhibits growth of the mycelial form of C. albicans (MIC=6.25 μg/mL) and potentiates the activity of polymyxin B against the multidrug-resistant pathogenic bacterium B. cenocepacia.
|
-
- HY-153221
-
|
CDK
|
Cancer
|
QR-6401 is an orally active and selective macrocyclic CDK2 inhibitor with IC50 values of 0.37, 10, 22, 34 and 45 nM for CDK2/E1, CDK9/T1, CDK1/A2, CDK6/D3 and CDK4/D1, respectively. QR-6401 has potent antitumor activity in an OVCAR3 ovarian cancer xenograft model. QR-6401 has the potential to be used in the study of cancer .
|
-
- HY-144451
-
|
Trk Receptor
|
Cancer
|
TRK-IN-12 (Compound 9e) is a potent inhibitor of TRK (TRK G595R IC50 = 13.1 nM). TRK-IN-12 is a macrocyclic derivative compound. TRK-IN-12 shows significant antiproliferative activity in the Ba/F3-LMNA-NTRK1 cell line (IC50 = 0.080 μM). TRK-IN-12 has shown a better inhibitory effect (IC50 = 0.646 μM) than control agent LOXO-101 in Ba/F3-LMNA-NTRK1-G595R cell line .
|
-
- HY-103048A
-
|
PD-1/PD-L1
|
Cancer
|
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
|
-
- HY-103048
-
|
PD-1/PD-L1
|
Cancer
|
PD-1/PD-L1-IN 3, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 can be used for the research of various diseases, including cancer and infectious diseases .
|
-
-
-
HY-L041
-
|
405 compounds
|
Macrocycles, molecules containing 12-membered or larger rings, are receiving increased attention in small-molecule drug discovery. The reasons are several, including providing access to novel chemical space, challenging new protein targets, showing favorable ADME- and PK-properties. Macrocycles have demonstrated repeated success when addressing targets that have proved to be highly challenging for standard small-molecule drug discovery, especially in modulating macromolecular processes such as protein–protein interactions (PPI). Otherwise, the size and complexity of macrocyclic compounds make possible to ensure numerous and spatially distributed binding interactions, thereby increasing both binding affinity and selectivity.
MCE offers a unique collection of 405 macrocyclic compounds which can be used for drug discovery for high throughput screening (HTS) and high content screening (HCS). MCE Macrocyclic Compound Library is a useful tool for discovering new drugs, especially for “undruggable” targets and protein–protein interactions.
|
-
-
HY-L0119V
-
|
3,253 compounds
|
Protein protein interactions (PPI) have pivotal roles in life processes. The studies showed that aberrant PPI are associated with various diseases. However, the design of modulators targeting PPI still faces tremendous challenges, such the difficult PPI interfaces for the drug design, lack of ligands reference, lack of guidance rules for the PPI modulators development and high-resolution PPI proteins structures.
The PPI Library comprises molecules of various sizes, frameworks, and shapes ranging from fragment-like entities to macrocyclic derivatives designed as secondary structure mimetics or as epitope mimetics. The designs cover β-turn / loop mimetics and α-helix mimetics. Since helices present at the interface in 62% of all protein-protein interactions. This library focused on designs including mimics with the substitution geometry of an a-helices, as well as designs that mimic the location of “hot-spot” side chains in helix-mediated PPIs.
|
Cat. No. |
Product Name |
Type |
-
- HY-W034566
-
Hexaaza-18-crown-6; 1,4,7,10,13,16-Hexaazacyclooctadecane
|
Biochemical Assay Reagents
|
Hexacyclen is an organic compound with a unique macrocyclic structure composed of six nitrogen-containing rings. It is commonly used as a chelating agent in chemistry and biochemistry due to its ability to bind metal ions. Inhibitors of certain diseases such as cancer. In biochemistry, Hexacyclen is often used to selectively bind metal ions in proteins or enzymes to study their structure and function. Due to its large size and complex structure, Hexacyclen is not widely used in daily products or applications .
|
-
- HY-W034576
-
Hexaaza-18-crown-6 hexahydrochloride; 1,4,7,10,13,16-Hexaazacyclooctadecane hexahydrochloride
|
Biochemical Assay Reagents
|
Hexacyclen (Cycloalkene) is an organic compound with a unique macrocyclic structure composed of six nitrogen-containing rings. Hexacyclen is commonly used as a chelating agent in chemistry and biochemistry due to its ability to bind metal ions, and is often used to selectively bind metal ions in proteins or enzymes to study their structure and function. Hexacyclen also acts as an inhibitor of cancer .
|
-
- HY-W034566A
-
Hexaaza-18-crown-6 trisulfate; 1,4,7,10,13,16-Hexaazacyclooctadecane trisulfate
|
Biochemical Assay Reagents
|
Hexacyclen, also known as cycloalkene, is an organic compound with a unique macrocyclic structure composed of six nitrogen-containing rings. It is commonly used as a chelating agent in chemistry and biochemistry due to its ability to bind metal ions. Inhibitors of certain diseases such as cancer. In biochemistry, Hexacyclen is often used to selectively bind metal ions in proteins or enzymes to study their structure and function. Due to its large size and complex structure, Hexacyclen is not widely used in daily products or applications.
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P3502
-
RA101495; RA3193
|
Complement System
|
Inflammation/Immunology
|
Zilucoplan (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan can be used in research of immune-mediated necrotising myopathy (IMNM) .
|
-
- HY-P5963
-
-
- HY-P10375
-
|
PD-1/PD-L1
|
Inflammation/Immunology
Cancer
|
BMS-986189 is a macrocyclic peptide PD-1/PD-L1 interaction with an IC50 of 1.03 nM inhibitor. BMS-986189 can be used for cancer research, such as human lung carcinoma cells L2987 .
|
-
- HY-P10676
-
|
Peptides
|
Cancer
|
cMCF02A is a potent inhibitory peptide of the MAGE-A4 binding axis and can be used in melanoma-related research .
|
-
- HY-P3270
-
|
Bacterial
Antibiotic
|
Infection
|
Capreomycin is a macrocyclic peptide antibiotic. Capreomycin can be used for anti-multidrug-resistant-tuberculosis research. Capreomycin can inhibit phenylalanine synthesis in in mycobacterial ribosomes translation
|
-
- HY-P2331
-
Antibiotic A 3802-IV-3; Gardimycin
|
Antibiotic
|
Infection
|
Actagardin is a tetracyclic lantibiotic produced by several species of Actinoplanes. It is composed of macrocyclic rings formed by thioether bridges. Actagardin preferably targets Gram-positive bacteria, inhibiting the synthesis of peptidoglycan.
|
-
- HY-158150
-
|
Proteasome
|
Cancer
|
20S Proteasome-IN-5 (Compound 5) is a macrocyclic inhibitor of the 20S Proteasome, with IC50 values of 0.19 and 52.5 μM for ChT-L and PGPH-L activity, respectively .
|
-
- HY-172320
-
|
PD-1/PD-L1
|
Cancer
|
BMS-986238, a second-generation macrocyclic peptide, is a potent PD-L1 inhibitor. BMS-986238 has the potential for the study of solid tumours and lymphomas (cancer of the lymphatic system) .
|
-
- HY-P3502A
-
RA101495 TFA; RA3193 TFA
|
Complement System
|
Inflammation/Immunology
|
Zilucoplan TFA (RA101495), a 15-amino acid macrocyclic peptide, is a potent complement component 5 (C5) inhibitor. Zilucoplan TFA can be used in research of immune-mediated necrotising myopathy (IMNM) .
|
-
- HY-P10700
-
|
Antibiotic
|
Infection
|
RO7196472 is a potent and selective macrocyclic peptide antibiotic that targets Acinetobacter strains. RO7196472 inhibits Acinetobacter strain activity by specifically binding to the Lipopolysaccharide (LPS) binding site on the LptB2FG complex located on the inner membrane of Acinetobacter strains, thereby blocking LPS transport and suppressing Acinetobacter strain activity .
|
-
- HY-P10855
-
|
SARS-CoV
|
Infection
|
S1b3inL1 is a SARS-CoV-2 spike protein macrocyclic peptide inhibitor. S1b3inL1 can bind the conserved site of spike protein with high affinity and inhibit the infection of various SARS-CoV-2 variant strains. S1b3inL1 has antiviral activity .
|
-
- HY-P10477
-
|
Peptides
|
Cancer
|
CT-08 (CT8, Compound 3) is a macrocyclic Sec61 modulator, blocks protein secretion in a signal sequence-dependent manner. CT-08 blocks Sec61-mediated translocation of VCAMss-GLuc into the ER, resulting in a loss of luciferase activity. CT-08 inhibits VCAM expression in transfected cells .
|
-
- HY-P3143
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-P3143A
-
|
PD-1/PD-L1
|
Cancer
|
BMSpep-57 hydrochloride is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 hydrochloride binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 hydrochloride facilitates T cell function by in creasing IL-2 production in PBMCs .
|
-
- HY-149034
-
S5
|
Influenza Virus
|
Infection
Cancer
|
Influenza A virus-IN-8 (S5) is a macrocyclic peptide with no cytotoxic. Influenza A virus-IN-8 is also a potent Influenza A Virus (IAV) inhibitor (with sufficient protease stability) with IC50s of 6.7 and 6.6 nM for H1 and H5 variants, respectively. Influenza A virus-IN-8 shows good affinitiescan to H1 variants, binds to a conserved region in the HA stem with a Kd of 1.0 nM .
|
-
- HY-103048A
-
|
PD-1/PD-L1
|
Cancer
|
PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-13756S
-
|
Tacrolimus- 13C,d2 is a 13C-labeled and deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
|
-
-
- HY-17580S
-
|
Fidaxomicin-d7 (OPT-80-D7) is the deuterium labeled Fidaxomicin. Fidaxomicin (OPT-80), a macrocyclic RNA polymerase inhibitor, has a narrow spectrum of activity. Fidaxomicin selectively eradicates pathogenic Clostridium difficile with minimal disruption to the multiple species of bacteria that make up the normal, healthy intestinal flora .
|
-
-
- HY-13756S2
-
|
Tacrolimus-d3 (FK506-d3) is deuterium labeled Tacrolimus. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties .
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: